Professor Gene Yeo, Sanford Labs’ Chief Scientist and Co-Founder, and colleagues identified a new player in brain immune biology: an RNA-binding protein called ARID5A that acts as a hidden coordinator inside microglia — the brain’s resident immune cells and first responders to damage and disease.

Microglia are supposed to clean up debris, respond to amyloid-beta plaques in Alzheimer’s disease and calibrate inflammation. When they malfunction, three things tend to go wrong together — immune signaling spirals, the cell’s lysosomal “recycling system” falters and iron builds up, eventually triggering a form of cell death called ferroptosis.

Prof. Yeo and colleagues found that an RNA binding protein ARID5A sits right at the intersection of all three.

Using stem-cell-derived human microglia, they mapped where ARID5A binds across the genome and transcriptome and showed it directly shapes:

🧬 Splicing of a key lysosomal enzyme (GCase, tied to Parkinson’s disease)
🦠 Translation of immune/interferon genes, tuning how “activated” microglia become
⚙️ Iron metabolism genes, controlling susceptibility to ferroptosis

When ARID5A was removed, microglia became more resistant to ferroptosis — and so did neighboring neurons in co-culture, showing this iron-handling program in microglia can directly protect neurons.

Even more intriguing: in microglia carrying a disease-causing TREM2 mutation (linked to a rare neurodegenerative disorder), dialing down ARID5A partially restored healthy behavior — improved amyloid-beta clearance and better cell survival.

Why does this matter? This work shows that a single RNA-binding protein can function as a molecular hub linking immunity, waste clearance, and metal-ion biology — three pathways usually studied in isolation. It’s a reminder that RNA-binding proteins aren’t just background machinery; they’re active decision-makers in cell identity and disease.

For neurodegeneration research, it also points to something exciting: modulating one RBP could simultaneously correct multiple dysfunctional pathways in microglia, rather than requiring separate interventions for inflammation, lysosomal dysfunction, and iron toxicity.

VIEW ALL LATEST NEWS